Interim Phase 1b/2 data on AU-011 presented by Carol Shields, M.D., at AAO 2017 show safety and preliminary efficacy at three months post-treatment.
We are Developing a New Class of Therapies to Target and Destroy Cancer Cells Selectively
Current treatments for cancers like ocular melanoma are highly invasive and often imprecise and toxic. We are creating a new class of therapies that can pinpoint solid tumors and metastases without harming surrounding tissue, enabling targeted treatment across a wide range of cancers.
Dr. Jay Duker has been a practicing ophthalmologist for more than 30 years and is also a professor as well as head of a prominent center of care in the Boston area, the New England Eye Center. In this Q&A, Dr. Duker shares his thoughts on how ocular melanoma (OM) treatment has evolved over the years and what advances are on the horizon.
The first time I heard the words, “ocular melanoma” was at The University of Colorado Cancer Center in Denver.
My healthy husband, Gregg, who, at the age of 34, had never had an eye exam in his life, had just been diagnosed with OM.